In a study in high-fed diet mice, when osteopontin expression was neutralized by antibodies, insulin resistance was reduced, suggesting that osteopontin may be a potential pharmaceutical target for cardiometabolic disorders in subjects with obesity [63]. Here, SPP1 is linked to Insulin resistance.